Stage I seminoma: Outcome of different treatment modalities and changes in patterns of care. A single institution experience
https://doi.org/10.4081/aiua.2023.11057
Accepted: January 3, 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Background: The mainstay for management of stage I seminoma is high inguinal orchiectomy with post-orchiectomy therapeutic options including active surveillance, chemotherapy or radiation therapy.
Objectives: To analyze different post-orchiectomy treatment modalities outcomes of stage I seminoma patients presented to NCI, Cairo University in the period from 2005-2019.
Patients and methods: A retrospective review of all patients' records with clinical stage I seminoma who presented to our institute in the period from 2005-2019 was done. Adjuvant treatment details were extracted and we compared overall survival (OS) and disease free survival (DFS) for different modalities and changes in patterns of care over this period.
Results: Thirty five patients were identified with thirty three patients eligible for analysis. Median age was 35 years (range, 19-52). Fourteen patients were kept under active surveillance, eleven patients received adjuvant carboplatin and eight patients received adjuvant radiation to para-aortic chain. Five-year OS was 100% for all patients regardless post-operative approach. Five-year DFS was 100% for patients who received adjuvant chemotherapy or radiotherapy versus 93% for patients who were kept under active surveillance (p=0.03).
Conclusion: Clinical stage I seminoma is a favorable disease entity with favorable disease related outcomes regardless post-operative approach. Active surveillance is reasonable and safe given equal survival to active treatment.
SEER Cancer Statistics Factsheets: Testicular Cancer. National Cancer Institute. Bethesda, MD. 2020.
Jones RH, Vasey PA. Part I: testicular cancer--management of early disease. Lancet Oncol. 2003; 4:730-7. DOI: https://doi.org/10.1016/S1470-2045(03)01278-6
Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011; 103:241-9. DOI: https://doi.org/10.1093/jnci/djq525
Glaser SM, Vargo JA, Balasubramani GK, Beriwal S. Surveillance and Radiation Therapy for Stage I Seminoma-Have We Learned From the Evidence? Int J Radiat Oncol Biol Phys. 2016; 94:75-84. DOI: https://doi.org/10.1016/j.ijrobp.2015.09.028
SEER Cancer Statistics Factsheets: Testicular Cancer. National Cancer Institute. Bethesda, MD. 2016.
André Marques-Pinto, Ana Inês Gomes, Joana Febra, et al. Specialist management of testicular cancer: Report of the last 10 years at a Portuguese tertiary referral academic Centre. Arch Ital Urol Androl. 2021; 93:153-157. DOI: https://doi.org/10.4081/aiua.2021.2.153
Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of car-boplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011; 29:957-62. DOI: https://doi.org/10.1200/JCO.2009.26.4655
Dieckmann KP, Dralle-Filiz I, Matthies C, et al. Testicular semi-noma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol. 2016; 142:1599-607. DOI: https://doi.org/10.1007/s00432-016-2162-z
Tandstad T, Ståhl O, Dahl O, et al. Treatment of stage I semino-ma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016; 27:1299-304. DOI: https://doi.org/10.1093/annonc/mdw164
Zengerling F, Kunath F, Jensen K, et al. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergo-ing surveillance-A systematic review. Urol Oncol. 2018; 36:448-458. DOI: https://doi.org/10.1016/j.urolonc.2017.06.047
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for testicular cancer V.2.2022. ©National Comprehensive Cancer Network, Inc. 2022.
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
